These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31943866)

  • 1. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
    Kim SC; Sarpatwari A; Landon JE; Desai RJ
    Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866
    [No Abstract]   [Full Text] [Related]  

  • 2. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.
    Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK
    J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
    Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
    Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
    Becciolini A; Raimondo MG; Crotti C; Agape E; Biggioggero M; Favalli EG
    Drug Des Devel Ther; 2017; 11():1969-1978. PubMed ID: 28721016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
    Araújo FC; Gonçalves J; Fonseca JE
    Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
    Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
    Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
    Curtis JR; Xie F; Kay J; Kallich JD
    Arthritis Res Ther; 2019 Dec; 21(1):285. PubMed ID: 31831064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in Inflammatory Bowel Disease.
    Buchner AM; Schneider Y; Lichtenstein GR
    Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.
    Sung YK; Jung SY; Kim H; Choi S; Im SG; Lee YS; Jang EJ; Cho SK
    PLoS One; 2020; 15(1):e0227960. PubMed ID: 31978121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
    Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S
    Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
    Yazdany J; Dudley RA; Lin GA; Chen R; Tseng CW
    JAMA; 2018 Sep; 320(9):931-933. PubMed ID: 30193264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.
    Stajszczyk M; Obarska I; Jeka S; Batko B
    Ann Rheum Dis; 2023 Sep; 82(9):1171-1180. PubMed ID: 37328194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.
    Vasudevan A; Ip F; Liew D; van Langenberg DR
    Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
    Kim SC; Choi NK; Lee J; Kwon KE; Eddings W; Sung YK; Ji Song H; Kesselheim AS; Solomon DH
    Arthritis Rheumatol; 2016 May; 68(5):1076-9. PubMed ID: 26662931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.